HydroVax-001 experimental vaccine was discovered and developed by scientists at the Oregon National Primate Research Center at Oregon Health & Science University (OHSU) in Portland.
The scientists were funded with a $7.2 million grant awarded in 2009 from NIAID, part of the National Institutes of Health.
The new vaccine is being tested in a Phase 1 clinical trial at Duke University in Durham, N.C., one of NIAID’s Vaccine and Treatment Evaluation Units (VTEUs).
The OHSU research team, led by senior scientist Mark Slifka, Ph.D., created the investigational vaccine, HydroVax-001, with a novel, hydrogen peroxide-based process that renders the virus inactive while still maintaining key immune-system triggering surface structures.
Because the virus used to make the vaccine is inactivated, the experimental vaccine likely could be used in a diverse population, including immunologically vulnerable groups, such as the elderly, NIAID said.